George Zavoico

As Novavax, Inc. (NASDAQ: NVAX) approaches two key dates in its pipeline, bulls are preparing to profit. The Rating B Riley FBR analysts George Zavoico and Dylan Dupuis maintained a Buy rating on Novavax with a $10 price target. The Thesis The biotech will complete two clinical trials in the first...

With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst George Zavoico initiated coverage of Pluristem Therapeutics Inc. (NASDAQ: PSTI)...

Analysts at B. Riley FBR initiated coverage of Novavax, Inc. (NASDAQ: NVAX) on Jan. 5 with a Buy rating and $2.25 price target. Just five days later, the firm turned uber-bullish on the stock. The Analyst George Zavoico maintains a Buy rating on Novavax's stock with a 12-month price target...

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a therapeutic and diagnostic antibody development and manufacturing company based in Tustin, CA, has had a tumultuous ride in the past 12 months. The news coming out of Peregrine has alternated between very bad to excellent several times. Now,...